首页> 外文学位 >Dissecting the non-canonical functions of p53 through novel target identification and p53 acetylation.
【24h】

Dissecting the non-canonical functions of p53 through novel target identification and p53 acetylation.

机译:通过新颖的靶标鉴定和p53乙酰化分析p53的非规范功能。

获取原文
获取原文并翻译 | 示例

摘要

It is well established that the p53 tumor suppressor plays a crucial role in controlling cell proliferation and apoptosis upon various types of stress. There is increasing evidence showing that p53 is also critically involved in various non-canonical pathways, including metabolism, autophagy, senescence and aging. Through a ChIP-on-chip screen, we identified a novel p53 metabolic target, pantothenate kinase-1 (PANK1). PanK1 catalyzes the rate-limiting step for CoA synthesis, and therefore, controls intracellular CoA content; Pank1 knockout mice exhibit defect in beta-oxidation and gluconeogenesis in the liver after starvation due to insufficient CoA levels. We demonstrated that PANK1 gene is a direct transcriptional target of p53. Although DNA damage-induced p53 upregulates PanK1 expression, depletion of PanK1 expression does not affect p53-dependent growth arrest or apoptosis. Interestingly, upon glucose starvation, PanK1 expression is significantly reduced in HCT116 p53 (-/-) but not in HCT116 p53 (+/+) cells, suggesting that p53 is required to maintain PanK1 expression under metabolic stress conditions. Moreover, by using p53-mutant mice, we observed that PanK activity and CoA levels are lower in livers of p53-null mice than that of wild-type mice upon starvation. Similar to the case in Pank1 knockout mice, beta-oxidation and gluconeogenesis are impaired in p53-null mice. Together, our findings show that p53 is critical in regulating energy homeostasis through transcriptional control of PANK1.;Our study on PANK1 led us to the question of how p53 can differentially regulate a diverse array of downstream targets in a context-dependent manner. Studies have shown that p53 acetylation at K120 and K164 lysine residues contribute to p53-mediated apoptosis and growth arrest functions, which was further supported by the 3KR mouse model (K117/161/162R) that mirrors the K120/164R mutations in human p53. These studies also suggest that a potentially large number of p53 targets can still be regulated by p53 in the absence of K120/164 acetylation (K117/161/162R in mouse). To investigate whether additional modifications of p53 can further contribute to promoter-specific transactivation, we conducted a screen using mass spectrometry and identified a novel acetylation site at K101. Our data demonstrated that K101 in human p53, as well as the homologous K98 lysine residue in mouse p53, can be acetylated by acetyltransferase CBP. Acetylation at this novel site does not contribute to p53 stability or DNA-binding capabilities. Ablation of K98 acetylation in mouse p53 alone does not affect the transcriptional activity of p53. However, simultaneous loss of K98 acetylation with the previously characterized K117/161/162 acetylations (4KR98 p53) significantly abrogates p53-mediated activation of TIGAR and MDM2 genes.;The 3KR mouse model, although cannot elicit canonical p53-mediated apoptotic and cell cycle arrest responses, still retains the ability to suppress tumor formation. We, therefore, investigated whether other non-canonical targets of p53 could potentially mediate tumor suppression. By RNA-seq profiling of gene expression in cells expressing 3KR p53, we identified TNFRSF14 (tumor necrosis factor receptor superfamily, member 14) as a novel p53 target. The TNFRSF14 receptor has been shown to be frequently mutated in follicular lymphoma and diffuse large B cell lymphoma, and stimulation by its ligand LIGHT leads to cell death in many cancer cells. We report that TNFRSF14 is a novel p53 target that can be activated by 3KR p53. Interestingly, transactivation of TNFRSF14 is defective by 4KR98 p53. Furthermore, LIGHT ligand stimulates cell death in TNFRSF14-expressing cells and cells expressing 3KR p53, but not those expressing 4KR98 p53.;Altogether, our findings in these studies underscore the extensive scope of p53 functions and provide new insights into the versatility of non-canonical pathways. Not only does p53 mediate tumor suppression through both canonical and non-canonical downstream effectors, p53 can also contribute to cellular homeostasis and energy balance.
机译:公认的是,p53肿瘤抑制因子在控制各种压力下对细胞增殖和凋亡的控制中起着至关重要的作用。越来越多的证据表明,p53还关键参与了各种非经典途径,包括代谢,自噬,衰老和衰老。通过芯片上的芯片筛选,我们确定了一种新型的p53代谢靶标,泛酸激酶1(PANK1)。 PanK1催化CoA合成的限速步骤,因此控制细胞内CoA的含量。饥饿后,由于CoA水平不足,Pank1基因敲除小鼠的肝脏中存在β-氧化和糖异生的缺陷。我们证明PANK1基因是p53的直接转录目标。尽管DNA损伤诱导的p53上调了PanK1表达,但PanK1表达的耗尽并不影响p53依赖性生长停滞或凋亡。有趣的是,在葡萄糖饥饿时,HCT116 p53(-/-)细胞中PanK1表达显着降低,而HCT116 p53(+ / +)细胞中PanK1表达却没有降低,这表明在代谢应激条件下维持PanK1表达需要p53。此外,通过使用p53突变小鼠,我们观察到饥饿后p53无小鼠的肝脏PanK活性和CoA水平低于野生型小鼠。与Pank1基因敲除小鼠的情况相似,p53无效小鼠的β氧化和糖异生也受损。在一起,我们的发现表明p53在通过PANK1的转录控制来调节能量稳态中起着至关重要的作用。我们对PANK1的研究使我们提出了一个问题,即p53如何以上下文相关的方式差异地调控多种下游靶标。研究表明,K120和K164赖氨酸残基处的p53乙酰化有助于p53介导的凋亡和生长停滞功能,这一点得到反映人类p53中K120 / 164R突变的3KR小鼠模型(K117 / 161 / 162R)的进一步支持。这些研究还表明,在不存在K120 / 164乙酰化作用(小鼠中为K117 / 161 / 162R)的情况下,仍然可以通过p53调节潜在的大量p53靶标。为了研究p53的其他修饰是否可以进一步促进启动子特异性反式激活,我们使用质谱进行了筛选,并在K101处鉴定了一个新的乙酰化位点。我们的数据表明,人p53中的K101以及小鼠p53中的同源K98赖氨酸残基可以被乙酰基转移酶CBP乙酰化。在该新位点的乙酰化作用不影响p53的稳定性或DNA结合能力。单独在小鼠p53中消除K98乙酰化不会影响p53的转录活性。然而,同时丧失K98乙酰化作用和先前表征的K117 / 161/162乙酰化作用(4KR98 p53)可以显着消除p53介导的TIGAR和MDM2基因的激活。3KR小鼠模型,尽管不能引起经典的p53介导的凋亡和细胞周期。逮捕反应,仍然保留抑制肿瘤形成的能力。因此,我们研究了p53的其他非经典靶标是否可能介导肿瘤抑制。通过表达3KR p53的细胞中基因表达的RNA序列分析,我们确定TNFRSF14(肿瘤坏死因子受体超家族,成员14)为新型p53靶标。 TNFRSF14受体已被证明在滤泡性淋巴瘤中经常发生突变并扩散大B细胞淋巴瘤,其配体LIGHT的刺激导致许多癌细胞死亡。我们报告TNFRSF14是可以被3KR p53激活的新型p53靶标。有趣的是,TNFRSF14的反式激活被4KR98 p53破坏。此外,LIGHT配体可刺激表达TNFRSF14的细胞和表达3KR p53的细胞死亡,但不刺激表达4KR98 p53的细胞死亡。总的来说,我们在这些研究中的发现强调了p53功能的广泛范围,并为非规范途径。 p53不仅通过规范的和非规范的下游效应子介导肿瘤抑制,而且p53还可以促进细胞稳态和能量平衡。

著录项

  • 作者

    Wang, Shang-Jui.;

  • 作者单位

    Columbia University.;

  • 授予单位 Columbia University.;
  • 学科 Biology Cell.;Biology Molecular.
  • 学位 Ph.D.
  • 年度 2014
  • 页码 153 p.
  • 总页数 153
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号